Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which eye drop stings less? small study pits flarex against lotemax SM

NCT ID NCT07588074

Completed Symptom relief Sponsor: Harrow Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested how comfortable two prescription steroid eye drops feel right after use. Forty adults with eye inflammation or dry eye received one drop of Flarex in one eye and one drop of Lotemax SM in the other. They rated comfort and vision impact at 30 seconds, 5 minutes, and 10 minutes. The goal was to see which drop is easier to tolerate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
fluorometholone acetate ophthalmic suspension 0.1% (Flarex) and loteprednol etabonate ophthalmic gel 0.38% (Lotemax SM)
What this could lead to
If one drop is clearly more comfortable, doctors may prefer it for patients who need steroid eye drops.
What could go wrong
This was a very small, single-dose study in 40 people, so results may not apply to long-term use or to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLERGIC CONJUNCTIVITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic conjunctivitis dry eye syndrome keratoconjunctivitis Postoperative Complications

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRY EYE DISEASE (DED) DRY EYE SYNDROMES KERATO CONJUNCTIVITIS SICCA KERATOCONJUNCTIVITIS OCULAR INFLAMMATION POST-OPERATIVE COMPLICATIONS POSTOPERATIVE COMPLICATIONS

Contacts and locations

Locations

  • Williamson Eye Center

    Baton Rouge, Louisiana, 70806, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.